Compare WKEY & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | COCP |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.6M | 21.6M |
| IPO Year | 2019 | 2011 |
| Metric | WKEY | COCP |
|---|---|---|
| Price | $5.84 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.50 | $6.00 |
| AVG Volume (30 Days) | 28.8K | ★ 50.9K |
| Earning Date | 01-28-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | $31.22 | N/A |
| Revenue Next Year | $91.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.32 | $0.76 |
| 52 Week High | $19.80 | $2.03 |
| Indicator | WKEY | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 52.68 |
| Support Level | $5.32 | $0.98 |
| Resistance Level | $6.94 | $1.22 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 14.49 | 26.53 |
WISeKey International Holding Ltd at the forefront of authentication and cybersecurity technology. It develops, markets, hosts, and supports a range of solutions that enable the secure digital identification and communication of people, content, and objects, by generating digital identities that enable its clients to monetize their existing user bases and, at the same time, expand their own eco-system securely by ensuring only authenticated objects and people can connect. The WISeKey Group operates through five core verticals: SEALSQ, WISeSat, SEALCOIN, WISeID, & WISe.ART. It has two business segments. Semiconductors & ASICs. The majority of its revenue is generated from the Semiconductors segment.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.